Ropinirole
| 證據等級: L5 | 預測適應症: 10 個 |
目錄
- Ropinirole
- Ropinirole: From No Registered Indication (Not Marketed in South Africa) to Attention-Deficit/Hyperactivity Disorder (Predicted)
Ropinirole: From No Registered Indication (Not Marketed in South Africa) to Attention-Deficit/Hyperactivity Disorder (Predicted)
One-Sentence Summary
Ropinirole is a non-ergot dopamine agonist with no original approved indication on file in this evidence pack — it is not currently marketed or registered in South Africa. The TxGNN model predicts potential relevance to Attention-Deficit/Hyperactivity Disorder (ADHD), but this direction is currently supported only by 0 clinical trials and 8 publications, most of which address the related restless legs syndrome (RLS)–ADHD comorbidity rather than direct evidence of ropinirole treating ADHD itself.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not documented — no SAHPRA registration or original indication is on file for ropinirole in this evidence pack |
| Predicted New Indication | Attention-Deficit/Hyperactivity Disorder (ADHD) |
| TxGNN Prediction Score | 99.99% (model rank 133) |
| Evidence Level | L4 |
| South Africa Market Status | Not Marketed |
| Number of SAHPRA Registrations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action (MOA) data for ropinirole is not available in this evidence pack, and there is no original approved indication on file — the drug is not currently marketed or registered in South Africa. Based on general pharmacological knowledge (not sourced from this dataset), ropinirole belongs to the non-ergot D2/D3 dopamine receptor agonist class, a group of medicines more commonly associated with Parkinson’s disease and restless legs syndrome in other markets.
The predicted link to ADHD does not rest on a direct MOA argument specific to ADHD. Instead, the supporting literature centers on the clinical overlap between restless legs syndrome and ADHD, both of which have been associated with dysregulated dopaminergic signalling. Only one publication — a single paediatric case report (PMID 15866437) — describes ropinirole use in a child, and even there the drug was prescribed for co-occurring RLS rather than for ADHD’s core symptoms directly.
Mechanistically, this is a hypothesis that needs careful distinction: ropinirole is a dopamine receptor agonist, whereas standard ADHD pharmacotherapy (e.g., methylphenidate, amphetamine salts) works by increasing synaptic dopamine/noradrenaline through reuptake inhibition or release — a different mechanism that happens to converge on the same neurotransmitter system. No clinical trial has tested ropinirole specifically for ADHD symptoms in the absence of comorbid RLS.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 16218085 | 2005 | Review | Sleep | Reviews the association between RLS and ADHD, discussing hypothesised shared dopaminergic mechanisms and the potential for common pharmacologic treatment when both conditions co-occur |
| 18656214 | 2008 | Review | Revue neurologique | General review of restless legs syndrome, including its overlap with other neurologic/behavioural conditions |
| 15866437 | 2005 | Case Report | Pediatric neurology | 6-year-old boy with ADHD (inadequately controlled on methylphenidate) and suspected RLS/periodic limb movement disorder; ropinirole improved both sleep disruption and ADHD symptoms |
| 30460371 | 2019 | Case Report (adverse effect) | Acta dermato-venereologica | Describes treatment-induced delusions of infestation associated with elevated brain dopamine levels from dopaminergic agents |
| 30950895 | 2019 | Case Report (adverse effect) | Cornea | Describes corneal edema in 3 patients exposed to systemic dopaminergic agents |
| 17483695 | 2007 | Preclinical | Journal of neuropathology and experimental neurology | Animal model (A11-lesioned, iron-deprived mice) of RLS-like increased locomotion, relevant to dopamine/iron pathophysiology |
| 34182128 | 2021 | Pharmacology | Pharmacological research | Studies heteromerization of α2A adrenoceptors with dopamine D4 receptor variants, relevant to impulsive-control disorders including ADHD, at a receptor-pharmacology level (does not test ropinirole directly) |
| 24992083 | 2014 | Other (different drug: piribedil) | Clinical neuropharmacology | Compares vigilance/cognitive effects of piribedil versus pramipexole and ropinirole in Parkinson’s disease patients with excessive daytime sleepiness — not an ADHD study |
Safety Considerations
Please refer to the SAHPRA-approved Professional Information (PI) for safety information. Report adverse drug reactions to SAHPRA.
No key warnings, contraindications, or drug interaction data were retrievable for ropinirole in this evidence pack — this is flagged as a Blocking data gap (DG001) that must be resolved before any safety assessment can proceed.
Conclusion and Next Steps
Decision: Hold
Rationale: The ADHD signal rests on indirect evidence — literature on RLS–ADHD comorbidity and a single paediatric case report — with no clinical trials and no confirmed mechanism-of-action data. Combined with the absence of any South African registration or PI-derived safety data, this candidate does not yet meet the bar for progression.
To proceed, the following is needed:
- SAHPRA-approved Professional Information (PI): warnings, precautions, and contraindications (Blocking gap, DG001)
- Confirmed mechanism of action data from DrugBank or equivalent source (High-priority gap, DG002)
- A prospective or retrospective study testing ropinirole specifically for ADHD symptoms (independent of comorbid RLS)
- Drug-drug interaction data relevant to typical ADHD comedications (e.g., stimulants, antidepressants)
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.